Amarin announced that it has reached agreement with the U.S. FDA under a Special Protocol Assessment for its planned Phase 3 clinical trial of AMR101 in patients with mixed dyslipidemia.
Newsbrief
FREE NEWSBRIEF SUBSCRIPTION
To receive the Scientist Live weekly email NewsBriefplease enter your details below
We use cookies to give you the best possible experience on this website. By continuing to use the website you agree to our use of cookies.
Close